AI-generated · cited to primary sources · not investment advice
Caplin Point Lab (524742) Mar 2024 Filing Analysis
How durable is the business?
Regulatory strength is expanding with 27 total approved ANDAs and a pipeline of 40+ more, alongside a successful USFDA inspection at the Gummidipoondi site. (2 expanding)
“As at end of the financial year, your Company had 27 ANDAs that stand approved from a total of 39 ANDAs filed.”
See the full cited Business Model analysis of Caplin Point Lab
What could break the thesis?
The risk is easing as the company moves toward backward integration. It acquired an API plant in Vizag and is completing an Oncology facility to bring production in-house. (2 easing)
“The intended Capex aims to enhance existing production capacities, widen the product range, and achieve backward integration for a majority of the products.”
See the full cited Risk analysis of Caplin Point Lab
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.